FDA Advisory Committee Conflict of Interest: USMLE Ethics

A new study in Health Affairs Scholar reports that patient and consumer representatives on U.S. Food and Drug Administration (FDA) advisory committees often have ties to advocacy organizations funded by drug companies. In a 10-year review, nearly 40% of advisory committee meetings included at least one representative with active ties to such organizations. The authors say these ties were often not disclosed, and they call for closer FDA scrutiny.

What happened

Researchers led by Genevieve Kanter, an associate professor at the USC Schaeffer Center for Health Policy & Economics, reviewed nearly 240 meetings of 12 FDA advisory committees held between 2013 and 2022. On average, each meeting included one patient representative and one consumer representative.

The main findings, as reported:

• Nearly 40% of meetings included at least one patient or consumer rep with active ties to an industry-funded advocacy organization.
• In 1 in 10 drug review meetings, a representative was affiliated with an organization that received support from the drug company under review.
• The ties were often not disclosed, according to the report.
• Every committee except those covering skin and eye drugs had at least one meeting with a patient representative tied to a pharma-funded advocacy group. Heart and kidney drug committees had the greatest share of such meetings (52%).
• In four committees, more than half of meetings had a consumer rep linked to a pharma-funded advocacy group: nervous system drugs (89%), GI drugs (67%), heart and kidney drugs (61%), and arthritis (53%).

The authors also cite earlier estimates that 68% of patient advocacy organizations, and 83% of the largest ones, receive donations from drug, device, and biotechnology companies.

The FDA may know about some of these relationships. A 2016 draft guidance asks for disclosure of financial ties that could create an appearance of conflict. The authors note that this type of tie is not considered a conflict requiring recusal under federal ethics laws, though it "may create the appearance that a member lacks impartiality."

Why it matters

FDA advisory committees review data on drugs and other products and give the agency recommendations. Patient and consumer representatives are included so that people who live with a disease, or who represent the public, have a voice in the discussion. Their perspective on tolerable risk, quality of life, and unmet need can be valuable.

The concern is that a voice presented as independent may be shaped by funding. Kanter said that, given how dependent some patient organizations are on industry support, it is reasonable to question whether these relationships affect how representatives vote.

The study does not show that these ties changed any vote or decision. It describes how common the ties are. That distinction matters for your exam reasoning as well as for reading the news.

What to know for the USMLE: conflict of interest and the FDA

Ethics questions on Step 1 and Step 2 CK rarely ask about this specific study. They do test the principles behind it.

• Conflict of interest (COI): a situation in which a secondary interest, such as financial gain, could unduly influence professional judgment about a primary interest, such as patient welfare or public health. A COI exists whether or not bias actually occurs.
• Actual vs. apparent conflict: the study's quote about the "appearance" of partiality is this distinction. An appearance of conflict can erode public trust even when no wrongdoing is proven.
• Disclosure vs. recusal: disclosure is the minimum step and makes the relationship visible. Recusal removes the person from the decision. Federal ethics rules did not require recusal for the ties in this study, which is why the debate centers on transparency.
• Transparency as a core professional value: physicians are expected to disclose relationships with industry, for example when speaking, publishing, or serving on guideline panels. In the U.S., the Physician Payments Sunshine Act (the Open Payments program) makes manufacturer payments to physicians publicly searchable.
• Sponsorship (funding) bias: industry-funded research tends to report favorable results more often. This is a classic bias category in biostatistics and evidence-based medicine questions.
• Role of FDA advisory committees: they give non-binding recommendations. The FDA makes the final decision on approval, though it often follows its panels.
• Drug development pathway: preclinical studies lead to an IND application, then Phase I (safety, pharmacokinetics in a small group), Phase II (preliminary efficacy and dose), and Phase III (large confirmatory trials). Next comes the NDA (or BLA for biologics) and FDA review, then Phase IV postmarketing surveillance. Advisory committee meetings usually occur around the review stage.
• Ethical principles: COI questions usually map onto beneficence, justice, and professionalism. Look for the answer that prioritizes patient or public welfare over personal or institutional gain.
• Study design in this news: a descriptive review of meetings over time is observational. It can estimate prevalence but cannot establish causation, such as whether ties changed votes.

A typical Step 2 CK ethics stem describes a physician with a financial relationship to a company and asks for the best next step. The usual answer is to disclose the relationship, and to step back from decisions where the conflict is significant. It is not to deny the relationship or assume it has no influence.

Limitations

• Source detail. This article relies on a news report of the study. The report does not describe how the ties were identified or classified, or how disclosure was assessed. Check the original paper (Health Affairs Scholar, 2026, DOI: 10.1093/haschl/qxag269) before citing exact figures.
• Descriptive, not causal. The findings show how common ties were. They do not show that representatives voted differently because of them.
• Ties vs. wrongdoing. Under federal ethics laws, the type of tie described is not treated as a conflict requiring recusal. An appearance of partiality is not proof of bias.
• Time frame and scope. The review covers 12 committees from 2013 to 2022. It may not reflect current practice or other FDA bodies.
• Unclear denominators. Some percentages are reported per committee and for different types of meetings. These groupings can be hard to compare without the full paper.
• Representatives' value. The study does not assess the benefits of patient input. Industry funding of an advocacy group does not by itself mean its input is unhelpful.

FAQ

What did the study find about FDA advisory committees?

It found that nearly 40% of the roughly 240 meetings reviewed (2013–2022) included at least one patient or consumer representative with active ties to an advocacy organization funded by industry. About 1 in 10 drug review meetings included a representative affiliated with an organization supported by the drug's company.

Does this mean FDA drug approvals are biased?

No. The study does not measure whether votes or approval decisions were influenced. It identifies a transparency problem and a possible source of undue influence that the authors say warrants closer FDA scrutiny.

How could this appear on the USMLE?

Most likely as an ethics question on conflict of interest, disclosure, or professional integrity. You might be asked to distinguish disclosure from recusal, to identify sponsorship bias, or to recall that FDA advisory panels are advisory only.

Key takeaways

• A 10-year review of about 240 FDA advisory meetings found that nearly 40% included a patient or consumer representative tied to an industry-funded advocacy group. The authors say these ties were often not disclosed.
• The study is descriptive. It shows that ties are common but not that they changed votes or drug decisions.
• For the USMLE, focus on the principles: conflict of interest, actual vs. apparent conflict, disclosure vs. recusal, sponsorship bias, and the non-binding role of FDA advisory committees.